2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 1999

Aberrant Expression of the GluN2B N-Methyl D-Aspartate Receptor Subunit in Osteoarthritic Chondrocytes Causes Disease-Associated Changes in Chondrocyte Phenotype through Altered Expression of Core Components of the Chondrocyte Circadian Clock

Osteoarthritis and Joint Biology – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 2367

Acceptance Rate and Sociological Factors Involved in the Switch from Originator to Biosimilar Etanercept (SB4)

Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

9:00AM-11:00AM: Abstract Number: 2183

Access to Prescription Drugs in Canada: Results from an Online Survey

Health Services Research Poster III – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 2402

Acoustic Emissions Generated By the Temporomandibular Joint of Patients with Juvenile Idiopathic Arthritis and Their Implication on Patient Assessment and Screening: A Pilot Study

Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

9:00AM-11:00AM: Abstract Number: 2070

Activated Tendon Stromal Cells Drive a Type 17 Immune Response Via CCL20: A Potential Role in the Pathogenesis of Enthesitis in Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2233

Activation and Deficiency of Circulating Mucosal-Associated Invariant T Cells in Patients with Gouty Arthritis

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 2109

Activation of T Follicular Helper Cells through Epigenetic Regulation By STAT1 and STAT4 in Lupus Patients

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2680

Activation Towards Health Self-Management in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2199

Active Disease and Follow up 18f-FDG-PET/CT in Patients with Giant Cell Arteritis. Which Treatment Is More Likely to Achieve Remission?

Imaging of Rheumatic Diseases Poster III: Other Modalities

9:00AM-11:00AM: Abstract Number: 2571

Adalimumab Serum Concentration Fails to Predict Achievement of Sustained Remission or Absence of Flare for Patients with Non-Radiographic Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 1986

Adalimumab:TNF Complexes Are Cleared More Efficiently By Human Osteoclasts Than Those with Etanercept through Fcg-Receptor Binding and Internalization

Osteoarthritis and Joint Biology – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 1996

Adenosine A2A Receptor (A2AR) Stimulation Enhances Mitochondrial Metabolism and Mitigates Reactive Oxygen Species-Mediated Mitochondrial Injury

Osteoarthritis and Joint Biology – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 2001

Adenosine A2A Receptor Stimulation Regulates Autophagy in Chondrocytes

Osteoarthritis and Joint Biology – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 1997

Adenosine A2A Receptors Maintain Chondrocyte and Cartilage Homeostasis By Maintaining Expression of Anti-Inflammatory Regulators (Nur-77) and Suppressing Expression of Pro-Inflammatory Mediators

Osteoarthritis and Joint Biology – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 2036

Adenosine Receptors Expression As Predictor of Response to Methotrexate Therapy in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Etiology and Pathogenesis Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].